MedTrace Logo

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

NCT00660062 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2014-12-09

No results posted yet for this study

Summary

The main purpose of this study is to investigate the relapse preventing efficacy of escitalopram in a dose range and nortriptylin in a single dose in patients having been treated successfully with a course of electroconvulsive treatment (ECT).

Conditions

Interventions

DRUG

escitalopram

10 mg daily

DRUG

escitalopram

20 mg daily dosage

DRUG

escitalopram

30 mg daily dosage

DRUG

nortriptyline

100 mg daily dosage

Sponsors & Collaborators

  • Hillerod Hospital, Denmark

    lead OTHER

Principal Investigators

  • Klaus Martiny, MD,PhD · Mental Health Center Copenhagen Department O

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00660062 on ClinicalTrials.gov